# Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

> **NCT01808950** · PHASE1,PHASE2 · TERMINATED · sponsor: **Spirig Pharma Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Nodular Basal Cell Carcinoma

## Interventions

- **DRUG:** 0.06% Resiquimod Gel - A
- **DRUG:** 0.06% Resiquimod Gel - B
- **DRUG:** 0.06% Resiquimod Gel - C

## Key facts

- **NCT ID:** NCT01808950
- **Lead sponsor:** Spirig Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** safety issues
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808950, "Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01808950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*